UK-based drugmaker Shire says that the Australian Department of Health and Aging at the Therapeutic Goods Administration (TGA) has approved Soaraze (diclofenac sodium) 3% gel for the management of actinic keratosis. The disease is the most frequently occuring form of carcinoma, and is linked with a 10% risk of developing invasive squamous cell carcinoma.
Shire added that the product, which is marketed and sold under license from fellow UK firm SkyePharma, will be launched in Australia during 2007.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze